Jonathan Schwartz

Company: Rocket Pharmaceuticals
Virtual Speaker

Job title: Chief Medical Officer

Seminars:

Optimizing AAV Clinical Safety: Evolving Immunomodulation in the Phase 1 Study of RP-A501 (AAV9.LAMP2B) in Danon Disease 2:00 pm

Overview of immunologic side effects associated with systemic AAV therapy Review of the safety and preliminary efficacy in the adult and pediatric cohorts of the Phase 1 Danon disease study Overview of complement activation and enhancements in the immunomodulatory regimen for the pediatric cohortRead more

day: Day 1 Tracks 2 PM